Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Online Resource
    Online Resource
    Wiley ; 2010
    In:  Pediatric Blood & Cancer Vol. 55, No. 7 ( 2010-12-15), p. 1300-1305
    In: Pediatric Blood & Cancer, Wiley, Vol. 55, No. 7 ( 2010-12-15), p. 1300-1305
    Abstract: The effectiveness of killer immunoglobulin‐like receptor (KIR) incompatible, alloreactive natural killer (NK) cells has been primarily documented in hematological malignancies following stem‐cell transplant. This effect has not been thoroughly evaluated for pediatric solid tumors. In this study, we evaluated KIR receptor‐ligand incompatibility of NK cells against osteosarcoma cell lines. Procedure Following the KIR receptor‐ligand mismatch model, MHC I cell surface expression and KIR ligand mRNA content of 3 osteosarcoma cell lines was determined by flow cytometry and quantitative reverse transcription‐polymerase chain reaction (qRT‐PCR), respectively. NK cells were isolated from healthy volunteer donor peripheral blood mononuclear cells (PBMCs) and KIR surface expression determined by flow cytometry. An Annexin‐V based flow cytometric killing assay was used to determine % of dying osteosarcoma target cells by donor NK effector cells. Results One of seven healthy volunteer donors tested lacked phenotypic expression of one KIR. However, variable expression of KIR ligands was observed in 3 osteosarcoma cell lines. The highest rates of dying cells were seen in osteosarcoma cells with the lowest KIR ligand expression. Following down‐regulation of KIR ligand expression, an increased susceptibility to NK cell‐mediated killing was observed in a previously NK‐resistant osteosarcoma cell line. Conclusions Variable MHC I and KIR ligand expression was observed in osteosarcoma cell lines and this resulted in variable susceptibility to NK cell‐mediated killing predicted by the degree of KIR receptor‐ligand incompatibility. Collectively, these data provide rationale for the study of KIR incompatible stem‐cell transplant for osteosarcoma, although further studies with fresh osteosarcoma samples are necessary. Pediatr Blood Cancer. 2010;55:1300–1305. © 2010 Wiley‐Liss, Inc.
    Type of Medium: Online Resource
    ISSN: 1545-5009 , 1545-5017
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2010
    detail.hit.zdb_id: 2130978-4
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages